Skip to main content

Table 2 The clinical characteristics of the 29 patients

From: Can 18F-fluorodeoxyglucose positron emission tomography predict the response to radioactive iodine therapy in metastatic differentiated thyroid carcinoma?

Factors All patients PD (n = 8) Non-PD (n = 21) p values
Age (years old) (mean ± S.D.) (range) 62.4 ± 15.4 (26–81) 72.0 ± 6.0 (65–81) 58.6 ± 16.5 (26–81) 0.035
Gender 0.481
 Male 12 (41.4%) 4 (13.8%) 8 (27.6%)  
 Female 17 (58.6%) 4 (13.8%) 13 (44.9%)  
Histology 1.000
 Papillary 21 (72.4%) 6 (20.6%) 15 (51.7%)  
 Follicular 8 (27.6%) 2 (7.0%) 6 (20.6%)  
Serum glucose level (mg/dl) (mean ± S.D.) (range) 110.1 ± 26.2 (84–204) 115.0 ± 29.9 (84–204) 109.1 ± 25.5 (92–175) 0.633
Number of measurable lesions (max = 5) 0.104
 One 18 (62.1%) 4 (13.8%) 14 (49.3%)  
 Two 6 (20.6%) 1 (3.4%) 5 (17.2%)  
 Three 4 (13.8%) 2 (7.0%) 2 (7.0%)  
 Four 1 (3.4%) 1 (3.4%) 0 (0%)  
Position of metastatic lesions 0.971
 Lung 18 (39.1%) 6 (13.0%) 12 (26.1%)  
 Lymph nodes 16 (34.8%) 6 (13.0%) 10 (21.7%)  
 Bone 8 (17.4%) 3 (6.5%) 5 (11.0%)  
 Liver 2 (4.3%) 0 (0%) 2 (4.3%)  
 Peritoneum 2 (4.3%) 0 (0%) 2 (4.3%)  
Cycle of therapy     0.630
 One 17 (58.5%) 4 (13.8%) 13 (44.9%)  
 Two 8 (17.4%) 2 (7.0%) 6 (20.6%)  
 Three 1 (3.4%) 0 (0%) 1 (3.4%)  
 More than three 3 (6.5%) 2 (7.0%) 1 (3.4%)  
Activity of RAI (GBq, mean ± S.D.) (range) 3.2 ± 1.2 (1.1–5.6) 3.4 ± 1.1 (1.1–5.6) 3.1 ± 1.2 (1.1–5.6) 0.940
Total activity of RAI (GBq, mean ± S.D.) (range) 23.9 ± 25.2 (1.1–37.0) 15.7 ± 17.1 (1.1–34.0) 18.2 ± 16.8 (1.1–37.0) 0.982
Tg before therapy (range) 1784.2 ± 4975.4 (0–24,892.4) 4032.7 ± 8761.9 (4.42–24,892.4) 884.8 ± 1978.4 (0–8610) 0.709
Change of Tg (range) −0.3 ± 0.6 (− 1.0–0.8) 1.0 ± 0.6 (− 1–0.8) −0.5 ± 0.5 (− 1–0.4) 0.042
RECIST evaluation after RAI (months) 10.2 ± 1.7 10.8 ± 0.9 9.9 ± 1.3 1.000